Head and Neck Squamous Cell Carcinoma

Oncology·MeSH: Squamous Cell Carcinoma of Head and Neck

Prevalence

14.0 / 100K

Incidence

6.0 / 100K/yr

55 drugs in development·24 companies·59 clinical trials

Drug Pipeline by Phase

Phase 3(15)

Drug	Company
Camrelizumab and Cetuximab	FATE THERAPEUTICS INC (FATE)
Camrelizumab and Chemotherapy	FATE THERAPEUTICS INC (FATE)
Cetuximab	FATE THERAPEUTICS INC (FATE)
EGFR-TKI inhibitor based on investigator's choice	Merus N.V. (MRUS)
Erbitux®	Amneal Pharmaceuticals, Inc. (AMRX)
Erbitux®	FATE THERAPEUTICS INC (FATE)
ficerafusp alfa (formerly BCA101)	Bicara Therapeutics Inc. (BCAX)
Investigator's Choice	Merus N.V. (MRUS)
MCLA-158 (petosemtamab)	Merus N.V. (MRUS)
pds0101	PDS Biotechnology Corp (PDSB)
petosemtamab	Merus N.V. (MRUS)
Petosemtamab (MCLA-158)	Merus N.V. (MRUS)
RPH-002	Amneal Pharmaceuticals, Inc. (AMRX)
RPH-002	FATE THERAPEUTICS INC (FATE)
Volrustomig	ASTRAZENECA PLC (AZN)

Phase 2(16)

Drug	Company
cemiplimab	West Pharmaceutical Services Inc. (WST)
Cemiplimab	ELI LILLY & Co (LLY)
cmp-001	CHECKMATE PHARMACEUTICALS, INC. (CMPI)
domvanalimab	GILEAD SCIENCES, INC. (GILD)
Dostarlimab	Merus N.V. (MRUS)
EOS-448	iTeos Therapeutics, Inc. (ITOS)
fdc fianlimab+cemiplimab	West Pharmaceutical Services Inc. (WST)
FID-007	Fulgent Genetics Inc. (FLGT)
FID007	Fulgent Genetics Inc. (FLGT)
gedeptin	GeoVax Labs, Inc. (GOVX)
GSK5764227	Merus N.V. (MRUS)
rtx-224	Rubius Therapeutics, Inc. (RUBY)
si-b001	NYMOX PHARMACEUTICAL CORP (NYMXF)
STRO-002 (luveltamab tazevibulin, luvelta)	SUTRO BIOPHARMA, INC. (STRO)
versamune hpv	PDS Biotechnology Corp (PDSB)
vidutolimod	CHECKMATE PHARMACEUTICALS, INC. (CMPI)

Phase 1(17)

Drug	Company
BI 770371	Amneal Pharmaceuticals, Inc. (AMRX)
BI 770371	FATE THERAPEUTICS INC (FATE)
Birinapant	IGM Biosciences, Inc. (IGMS)
Cetuximab	NEKTAR THERAPEUTICS (NKTR)
CLD-201 (SuperNova™ / SNV1)	Calidi Biotherapeutics Inc. (CLDI)
NKTR-0165	NEKTAR THERAPEUTICS (NKTR)
NKTR-255	NEKTAR THERAPEUTICS (NKTR)
NKTR-288	NEKTAR THERAPEUTICS (NKTR)
NKTR-422	NEKTAR THERAPEUTICS (NKTR)
Polymer-conjugated IL-15 Receptor Agonist NKTR-255	NEKTAR THERAPEUTICS (NKTR)
STRO-001	SUTRO BIOPHARMA, INC. (STRO)
STRO-003	SUTRO BIOPHARMA, INC. (STRO)
STRO-004	SUTRO BIOPHARMA, INC. (STRO)
stro-006	SUTRO BIOPHARMA, INC. (STRO)
stro-227	SUTRO BIOPHARMA, INC. (STRO)
tagmokitug	Coherus Oncology, Inc. (CHRS)
zimberelimab	GILEAD SCIENCES, INC. (GILD)

Preclinical(1)

Drug	Company
nktr-0166	NEKTAR THERAPEUTICS (NKTR)

Phase 1/Phase 2(2)

Drug	Company
GTAEXS617	RECURSION PHARMACEUTICALS, INC. (RXRX)
micvotabart pelidotin	Pyxis Oncology, Inc. (PYXS)

Phase 2/Phase 3(3)

Drug	Company
BNT113	BioNTech SE (BNTX)
ficerafusp alfa	Bicara Therapeutics Inc. (BCAX)
inbrx-106	Inhibrx Biosciences, Inc. (INBX)

Phase 4(1)

Drug	Company
Investigator's Choice of Therapy	Merus N.V. (MRUS)

BioSniper tracks 55 drugs in development for Head and Neck Squamous Cell Carcinoma across 24 companies.

There are 59 clinical trials targeting Head and Neck Squamous Cell Carcinoma tracked by BioSniper.

The estimated prevalence of Head and Neck Squamous Cell Carcinoma is approximately 14.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.